Do you want to read an article? Please log in or register.
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
Further Publications
Related content
RECOMMENDED
Breast Cancer
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Eur J Cancer
Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thurlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano G
doi: 10.1016/j.ejca.2024.113535
ESMO 2024
Gynecologic Cancer
KEYNOTE-A18: Pembrolizumab plus chemoradiotherapy improves PFS and OS in patients with high-risk, locally advanced cervical cancer
Skin Cancer
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
Eur J Cancer
Kött J, Zell T, Zimmermann N, Rünger A, Smit DJ, Abeck F, Geidel G, Hansen-Abeck I, Heidrich I, Weichenthal M, Ugurel S, Leiter U, Berking C, Gutzmer R, Schadendorf D, Zimmer L, Livingstone E, Wasielewski IV, Mohr P, Meier F, Haferkamp S, Drexler K, Herbst R, Kellner I, Utikal J, Wohlfeil SA, Pföhler C, Adam L, Terheyden P, Ulrich J, Meiss F, Möbes M, Welzel J, Schilling B, Ziller F, Kaatz M, Kreuter A, Sindrilaru A, Dippel E, Sachse M, Weishaupt C, Hüning S, Heinzerling L, Loquai C, Schley G, Gambichler T, Löffler H, Grabbe S, Schultz E, Devereux N, Hassel JC, Simon JC, Raap U, Assaf C, Klemke CD, Sunderkötter C, Hofmann SC, Wenk S, Tronnier M, Thies S, Heppt MV, Eggermont A, Schulze HJ, Zouboulis CC, Tüting T, Bauer AT, Schneider SW, Gebhardt C
doi: 10.1016/j.ejca.2024.115159
Gastrointestinal Cancer
Pancreatic Cancer Surveillance and Survival of High-Risk Individuals
JAMA Oncol
Blackford AL, Canto MI, Dbouk M, Hruban RH, Katona BW, Chak A, Brand RE, Syngal S, Farrell J, Kastrinos F, Stoffel EM, Rustgi A, Klein AP, Kamel I, Fishman E, He J, Burkhart R, Shin EJ, Lennon AM, Goggins M
doi: 10.1001/jamaoncol.2024.1930
SABCS 2024
Breast Cancer
OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer
ASCO 2024
Gynecologic Cancer
Estrogen-only hormone therapy may increase ovarian cancer risk, while estrogen-progestin combination may lower the risk of endometrial cancer
ESMO 2024
Genitourinary Cancer
EMBARK: Enzalutamide as monotherapy and in combination with leuprolide improves metastasis-free survival in patients with nmHSPC regardless of age
SABCS 2024
Breast Cancer
PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer
Lymphoma
Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma
Blood Cancer J
Keijzer K, de Boer JW, van Doesum JA, Noordzij W, Huls GA, van Dijk LV, van Meerten T, Niezink AGH
doi: 10.1038/s41408-024-01022-w